29
Views
4
CrossRef citations to date
0
Altmetric
Review

Analysis of patent applications relating to peroxisome proliferator-activated receptor (PPAR) ligands in 2004

Pages 1521-1530 | Published online: 28 Oct 2005

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ramkrishna Mandal, Meenakshi Singh, Amrutha A.V. Krishnan, Yogita H. Dahat, Yogesh P. Bharitkar, V. Ravichandiran & Abhijit Hazra. (2020) Semi-synthesis of a novel hybrid isoxazolidino withaferin via chemoselective and diastereoselective 1,3-dipolar nitrone cycloaddition reaction. Natural Product Research 34:15, pages 2208-2218.
Read now

Articles from other publishers (3)

Seema Thakur, Arunima Das & Tapas Das. (2021) 1,3-Dipolar cycloaddition of nitrones: synthesis of multisubstituted, diverse range of heterocyclic compounds. New Journal of Chemistry 45:26, pages 11420-11456.
Crossref
Vitomir Sunjic & Michael J. ParnhamVitomir Šunjić & Michael J. Parnham. 2011. Signposts to Chiral Drugs. Signposts to Chiral Drugs 29 43 .
Yukiyoshi Yamazaki, Kazutoyo Abe, Tsutomu Toma, Masahiro Nishikawa, Hidefumi Ozawa, Ayumu Okuda, Takaaki Araki, Soichi Oda, Keisuke Inoue, Kimiyuki Shibuya, Bart Staels & Jean-Charles Fruchart. (2007) Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor α agonists. Bioorganic & Medicinal Chemistry Letters 17:16, pages 4689-4693.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.